Evidence map›Paper›PMID 34660280›Full record

ReviewFrontiers in oncology2021

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions.

Shuhua Wei, Chunxiao Li, Mengyuan Li, Yan Xiong, Yuliang Jiang, Haitao Sun, Bin Qiu, Christopher J Lin, Junjie Wang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Local efficacy and safety of CT-guided Iodine-125 seed implantation in the treatment of recurrent malignant tumors: a retrospective study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Shuhua WeiDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
Chunxiao LiDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
Mengyuan LiDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
Yan XiongDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
Yuliang JiangDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
Haitao SunDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
Bin QiuDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
Christopher J LinUniversity of Southern California, Los Angeles, CA, United States.
Junjie WangDepartment of Radiation Oncology, Peking University 3rd Hospital, Beijing, China.
Peking University · CNPeking University Third Hospital · CNUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioactive iodine-125 (I-125) is the most widely used radioactive sealed source for interstitial permanent brachytherapy (BT). BT has the exceptional ability to deliver extremely high doses that external beam radiotherapy (EBRT) could never achieve within treated lesions, with the added benefit that doses drop off rapidly outside the target lesion by minimizing the exposure of uninvolved surrounding normal tissue. Spurred by multiple biological and technological advances, BT application has experienced substantial alteration over the past few decades. The procedure of I-125 radioactive seed implantation evolved from ultrasound guidance to computed tomography guidance. Compellingly, the creative introduction of 3D-printed individual templates, BT treatment planning systems, and artificial intelligence navigator systems remarkably increased the accuracy of I-125 BT and individualized I-125 ablative radiotherapy. Of note, utilizing I-125 to treat carcinoma in hollow cavity organs was enabled by the utility of self-expandable metal stents (SEMSs). Initially, I-125 BT was only used in the treatment of rare tumors. However, an increasing number of clinical trials upheld the efficacy and safety of I-125 BT in almost all tumors. Therefore, this study aims to summarize the recent advances of I-125 BT in cancer therapy, which cover experimental research to clinical investigations, including the development of novel techniques. This review also raises unanswered questions that may prompt future clinical trials and experimental work.

Indexed as

3D printing templatebrachytherapyhigh-dose-rateiodine-125low-dose-ratetumor

Identifiers

PMID34660280
PMCPMC8514864
OpenAlexW3203964242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.